Characterization of a receptor for C5a anaphylatoxin on human eosinophils
- PMID: 2912983
Characterization of a receptor for C5a anaphylatoxin on human eosinophils
Abstract
The complement anaphylatoxin peptide C5a is well known to activate human polymorphonuclear leukocytes through receptor-mediated processes. C5a has also been reported to activate eosinophils for both chemotaxis and hexose uptake. We characterized the receptor molecule for human C5a on human eosinophils and compared it with the receptor on human neutrophils. At 4 degrees C, uptake of 1 nM 125I-C5a reaches equilibrium within 10 min on both cell types. Binding of 125I-C5a occurs over a concentration range comparable to that which stimulates lysosomal enzyme release and hexose uptake in both cell types. Scatchard analyses of the data indicate the presence of two receptor populations on eosinophils; a high affinity receptor with 15,000-20,000 sites/cell and a Kd of 3.1 +/- 0.6 x 10(-11) M, and a low affinity receptor with approximately 375,000 sites/cell and a Kd of 1 x 10(-7) M. Parallel experiments with neutrophils indicate the presence of a single receptor population with approximately 90,000 sites/cell and a Kd of 4.8 +/- 0.1 x 10(-10)M. The eosinophil receptor molecule was further characterized by covalently cross-linking 125I-C5a to cells followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the solubilized material. Autoradiography indicates the presence of a dominant C5a-eosinophil receptor complex with an apparent mass of 60-65 kDa. The corresponding neutrophil-C5a receptor complex has an apparent mass of 50-52 kDa as observed by others. When the cross-linked 125I-C5a-receptor complex was treated with cyanogen bromide, different patterns were observed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis for neutrophils and eosinophils. Thus, human eosinophils have a receptor for C5a anaphylatoxin which appears to be distinct from the C5a receptor present on human neutrophils.
Similar articles
-
Solubilization of the functional C5a receptor from human polymorphonuclear leukocytes.J Biol Chem. 1988 Jan 5;263(1):520-6. J Biol Chem. 1988. PMID: 3335507
-
Identification of the polymorphonuclear leukocyte C5a receptor.J Biol Chem. 1985 Jun 25;260(12):7157-60. J Biol Chem. 1985. PMID: 3997862
-
Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN).J Immunol. 1985 Sep;135(3):2063-8. J Immunol. 1985. PMID: 4020139
-
Biochemistry and biology of anaphylatoxins.Complement. 1986;3(3):111-27. doi: 10.1159/000467889. Complement. 1986. PMID: 3542363 Review.
-
The properties of human C5a anaphylatoxin. The significance of C5a formation during hemodialysis.Contrib Nephrol. 1987;59:51-71. doi: 10.1159/000414615. Contrib Nephrol. 1987. PMID: 3327650 Review.
Cited by
-
Complement-induced impairment of the innate immune system during sepsis.Curr Allergy Asthma Rep. 2004 Sep;4(5):359-64. doi: 10.1007/s11882-004-0084-3. Curr Allergy Asthma Rep. 2004. PMID: 15283874 Review.
-
Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils.J Exp Med. 1998 Sep 21;188(6):1063-74. doi: 10.1084/jem.188.6.1063. J Exp Med. 1998. PMID: 9743525 Free PMC article.
-
Aptamers that bind to the human complement component receptor hC5aR1 interfere with hC5aR1 interaction to its hC5a ligand.Mol Biol Rep. 2018 Oct;45(5):851-864. doi: 10.1007/s11033-018-4231-7. Epub 2018 Jul 6. Mol Biol Rep. 2018. PMID: 29981048
-
A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.Biochem J. 1992 Nov 15;288 ( Pt 1)(Pt 1):261-6. doi: 10.1042/bj2880261. Biochem J. 1992. PMID: 1445269 Free PMC article.
-
Increased C5a receptor expression in sepsis.J Clin Invest. 2002 Jul;110(1):101-8. doi: 10.1172/JCI15409. J Clin Invest. 2002. PMID: 12093893 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources